Special Issue "The Roles of microRNAs in Cancer Aggressiveness and Drug Resistance"
Deadline for manuscript submissions: 30 September 2021.
Interests: cancer genomics; microRNA-mRNA interaction; aberrant RNA splicing; precision cancer biomarkers; molecular mechanisms underlying cancer drug resistance
Mature microRNAs are small noncoding regulatory RNAs of 21-25 nucleotides in length that complementarily target mRNAs to promote mRNA degradation and/or inhibit protein translation. Emerging data suggest that microRNA aberration may play critical roles in cancer development and progression. Particularly, genomic studies (both array- and sequencing-based) have accelerated the identification of microRNA involvement in the tumor pathogenesis. With scientific discoveries of oncogenic and tumor suppressive microRNAs and their roles in different cancer types, there is a great potential of developing microRNAs as precision biomarkers in cancer diagnosis and/or prognosis. Furthermore, several microRNAs tested in the preclinical models and clinical trials have shown promising therapeutic potentials, although finding an effective microRNA delivery system remains a challenge in microRNA-based therapeutics.
This Special Issue focuses on understanding the functional roles and molecular mechanisms of microRNAs in promoting cancer aggressiveness (i.e., metastasis) and treatment resistance. Novel strategies for developing microRNA-based biomarkers and therapeutics will be included, based on the functional/pathological implications of microRNAs in cancers.
Dr. Bi-Dar Wang
Dr. Luciane R Cavalli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- treatment resistance
- drug target